[en] Diabetes is characterized by a progressive decline of the pancreatic beta cell mass (BCM), which is responsible for insufficient insulin secretion and hyperglycemia. There are presently no reliable methods to measure non-invasively the BCM in diabetic patients. Our work describes a phage display-derived peptide (P88) that is highly specific to (FXYD2)-gamma-a expressed by human beta cells and is proposed as a molecular vector for the development of functionalized imaging probes. P88 does not bind to the exocrine pancreas and is able to detect in vitro down to ~156 human pancreatic islets/mm3 after conjugation to ultra-small particles of iron oxide (USPIO), as proven by the R2 measured on MR images. For in vivo evaluation, MRI studies were carried out on nude mice bearing Capan-2 tumours that also express (FXYD2)-gamma-a. A strong negative contrast was obtained subsequent to the injection of USPIO-P88, but not in negative controls. On human histological sections, USPIO-P88 seems to be specific to pancreatic beta cells, but not to duodenum, stomach or kidney tissues. USPIO-P88 represents thus a novel and promising tool for monitoring pancreatic BCM in diabetic patients. The quantitative correlation between BCM and R2 remains to be demonstrated in vivo, but the T2 mapping and the black pixel estimation after USPIO-P88 injection could provide important information for the future pancreatic BCM evaluation by MRI.
Research center :
CMMI - Centre de Recherche en Microscopie et Imagerie Médicale
Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic cell death in type 1 and type 2 diabetes. Many differences, few similarities. Diabetes 2005; 54(Suppl. 2): S97-S107.
Souza F, Freeby M, Hultman K, Simpson N, Herron A, Witkowsky P, Maffei A, Harris PE. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr Med Chem 2006; 13: 2761-2773.
Lin M, Lubag A, McGuire MJ, Seliounine SY, Tsyganov EN, Antich PP, Sherry AD, Brown KC, Sun X. Advances in molecular imaging of pancreatic beta cells. Front Biosci 2008; 13: 4558-4575.
Brom M, Andralojć K, Oyen WJ, Boerman OC, Gotthardt M. Development of radiotracers for the determination of the beta-cell mass in vivo. Curr Pharm Des 2010; 16: 1561-1567.
Ichise M, Harris PE. Imaging of beta-cell mass and function. J Nucl Med 2010; 51: 1001-1004.
Wang P, Medarova Z, Moore A. Molecular imaging: a promising tool to monitor islet transplantation. J Transplant 2011; 202915. doi:10.1155/2011/202915.
Weir GC, Bonner-Weir S. Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci 2013; 1281: 92-105. doi:10.1111/nyas.12031.
Saudek F, Jirák D, Girman P, Herynek V, Dezortová M, Kríz J, Peregrin J, Berková Z, Zacharovová K, Hájek M. Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. Transplantation 2010; 90: 1602-1606.
Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med 2006; 12: 144-148.
Andralojc K, Srinivas M, Brom M, Joosten L, de Vries IJ, Eizirik DL, Boerman OC, Meda P, Gotthardt M. Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. Diabetologia 2012; 55: 1247-1257. doi:10.1007/s00125-012-2491-7.
Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahrén B, Salehi A. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007; 354: 240-245.
Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, Hirsch J, Prince M, Maffei A, Mann JJ, Butler PC, Van Heertum R, Leibel RL, Ichise M, Harris PE. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009; 50: 382-389. doi:10.2967/jnumed.108.054866.
Cline GW, Zhao X, Jakowski AB, Soeller WC, Treadway JL. Islet-selectivity of G-protein coupled receptor ligands evaluated for PET imaging of pancreatic β-cell mass. Biochem Biophys Res Commun 2011; 412: 413-418. doi:10.1016/j.bbrc.2011.07.077.
Wang Y, Lim K, Normandin M, Zhao X, Cline GW, Ding YS. Synthesis and evaluation of [(18)F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass. Nucl Med Biol 2012; 39: 167-176. doi:10.1016/j.nucmedbio.2011.
Samli KN, McGuire MJ, Newgard CB, Johnston SA, Brown KC. Peptide-mediated targeting of the islets of Langerhans. Diabetes 2005; 54: 2103-2108.
Ueberberg S, Meier JJ, Waengler C, Schechinger W, Dietrich JW, Tannapfel A, Schmitz I, Schirrmacher R, Köller M, Klein HH, Schneider S. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic β- or α-cells in vivo. Diabetes 2009; 58: 2324-2334. doi:10.2337/db09-0658.
Ueberberg S, Schneider S. Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma in vivo. Regul Pept 2010; 160: 1-8. doi:10.1016/j.regpep.2009.11.017.
Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004; 9: 525-529.
Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013; 81: 136-147. doi:10.1111/cbdd.12055.
Otvos L Jr. Peptide-based drug design: Here and now. In Methods in Molecular Biology 494 - Peptide-Based Drug Design, Otvos L (ed). Humana: Totowa, NJ, 2008; 1-8.
Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010; 49: 1364-1376. doi:10.1021/bi901135x.
Burtea C, Laurent S, Port M, Lancelot E, Ballet S, Rousseaux O, Toubeau G, Vander Elst L, Corot C, Muller RN. Molecular MRI of VCAM-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J Med Chem 2009; 52: 4725-4742. doi:10.1021/jm9002654.
Burtea C, Laurent S, Lancelot E, Ballet S, Murariu O, Rousseaux O, Port M, Vander Elst L, Corot C, Muller RN. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm 2009; 6: 1903-1919. doi:10.1021/mp900106m.
Larbanoix L, Burtea C, Laurent S, Van Leuven F, Toubeau G, Vander Elst L, Muller RN. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol Aging 2010; 31: 1679-1689. doi:10.1016/j.neurobiolaging.2008.09.021.
Larbanoix L, Burtea C, Ansciaux E, Laurent S, Mahieu I, Vander Elst L, Muller RN. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease. Comparison with two cyclic heptapeptides derived from a randomized phage display library. Peptides 2011; 32: 1232-1243. doi:10.1016/j.peptides.2011.04.026.
Thayer AM. Improving peptides. Chem Eng News 2011; 9: 13-20.
Geering K. FXYD proteins: new regulators of Na-K-ATPase. Am J Physiol Renal Physiol 2006; 290: F241-F250.
Flamez D, Roland I, Berton A, Kutlu B, Dufrane D, Beckers MC, De Waele E, Rooman I, Bouwens L, Clark A, Lonneux M, Jamar JF, Goldman S, Maréchal D, Goodman N, Gianello P, Van Huffel C, Salmon I, Eizirik DL. A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)γa as a pancreatic beta cell-specific biomarker. Diabetologia 2010; 53: 1372-1383. doi:10.1007/s00125-010-1714-z.
Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Vander Elst L, Muller RN. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol 2012; 32: e36-48. doi:10.1161/ATVBAHA.112.245415.
Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1β-exposed human and rat islet cells. Diabetologia 2001; 44: 325-332.
Laurent S, Burtea C, Thirifays C, Häfeli UO, Mahmoudi M. Crucial ignored parameters on nanotoxicology: the importance of toxicity assay modifications and 'cell vision'. PLoS One 2012; 7: e29997. doi:10.1371/journal.pone.0029997.
Laurent S, Burtea C, Thirifays C, Rezaee F, Mahmoudi M. Significance of cell 'observer' and protein source in nanobiosciences. J Colloid Interface Sci 2013; 392: 431-445. doi:10.1016/j.jcis.2012.10.005.
Girman P, Berkova Z, Dovolilova E, Saudek F. How to use image analysis for islet counting. Rev Diabet Stud 2008; 5: 38-46. doi:10.1900/RDS.2008.5.38.
Cunha DA, Igoillo-Esteve M, Gurzov EN, Germano CM, Naamane N, Marhfour I, Fukaya M, Vanderwinden JM, Gysemans C, Mathieu C, Marselli L, Marchetti P, Harding HP, Ron D, Eizirik DL, Cnop M. Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis. Diabetes 2012; 61: 2763-2775. doi:10.2337/db12-0123.
Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986; 234: 179-186.
Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982; 157: 105-132.
Ikai A. Thermostability and aliphatic index of globular proteins. J Biochem 1980; 88: 1895-1898.
Di Gialleonardo V, de Vries EF, Di Girolamo M, Quintero AM, Dierckx RA, Signore A. Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus. Endocr Rev 2012; 33: 892-919. doi:10.1210/er.2011-1041.
Bosco D, Armanet M, Morel P, Niclauss N, Sgroi A, Muller YD, Giovannoni L, Parnaud G, Berney T. Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes 2010; 59: 1202-1210. doi:10.2337/db09-1177.
Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn Reson Med 2007; 58: 725-734.
Antkowiak PF, Stevens BK, Nunemaker CS, McDuffie M, Epstein FH. Manganese-enhanced magnetic resonance imaging detects declining pancreatic β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes. Diabetes 2013; 62: 44-48. doi:10.2337/db12-0153.
Zacharovová K, Berková Z, Jirák D, Herynek V, Vancová M, Dovolilová E, Saudek F. Processing of superparamagnetic iron contrast agent ferucarbotran in transplanted pancreatic islets. Contrast Media Mol Imaging 2012; 7(6): 485-493. doi:10.1002/cmmi.1477.
Kriz J, Jirak D, Berkova Z, Herynek V, Lodererova A, Girman P, Habart D, Hajek M, Saudek F. Detection of pancreatic islet allograft impairment in advance of functional failure using magnetic resonance imaging. Transpl Int 2012; 25: 250-260. doi:10.1111/j.1432-2277.2011.01403.x.
Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008; 108: 2064-2110. doi:10.1021/cr068445e.
Sosnovik DE, Nahrendorf M, Weissleder R. Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol 2008; 103: 122-130. doi:10.1007/s00395-008-0710-7.
Moore A. Advances in beta-cell imaging. Eur J Radiol 2009; 70: 254-257.
Wang P, Yoo B, Yang J, Zhang X, Ross A, Pantazopoulos P, Dai G, Moore A. GLP-1R-targeting magnetic nanoparticles for pancreatic islet imaging. Diabetes 2014; 63: 1465-1474. doi:10.2337/db13-1543.
Burtea C, Laurent S, Mahieu I, Larbanoix L, Roch A, Port M, Rousseaux O, Ballet S, Murariu O, Toubeau G, Corot C, Vander Elst L, Muller RN. In vitro biomedical applications of functionalized iron oxide nanoparticles, including those not related to magnetic properties. Contrast Media Mol Imaging 2011; 6: 236-250.
Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M, Czernichow P, Scharfmann R. A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin secretion. J Clin Invest 2011; 121: 3589-3597. doi:10.1172/JCI58447.
Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM, Stetler-Stevenson WG. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003; 162: 1431-1439.
Purhonen P, Thomsen K, Maunsbach AB, Hebert H. Association of renal Na, K-ATPase alpha-subunit with the beta- and gamma-subunits based on cryoelectron microscopy. J Membr Biol 2006; 214: 139-146.
In't Veld P, Marichal M. Microscopic anatomy of the human islet of Langerhans. Adv Exp Med Biol 2010; 654: 1-19. doi:10.1007/978-90-481-3271-3_1.
